Minerva Neurosciences (NERV) Net Cash Flow (2013 - 2026)
Minerva Neurosciences (NERV) posted Net Cash Flow of -$49.6 million for Q1 2026, down 170.88% on a QoQ basis from $70.0 million in Q4 2025, and down 1118.45% year-over-year from $4.9 million in Q1 2025.
Minerva Neurosciences (NERV) Net Cash Flow (2013 - 2026) Analysis & Trends
Minerva Neurosciences' Net Cash Flow history runs 14 years deep, the most recent figure standing at -$49.6 million for Q1 2026.
- Quarterly Net Cash Flow fell 1118.45% year-over-year to -$49.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $15.4 million (up 187.9% YoY) and the FY2025 annual result came in at $61.0 million, up 411.76% from the prior year.
- Net Cash Flow was -$49.6 million for Q1 2026 at Minerva Neurosciences, down from $70.0 million in the prior quarter.
- Across five years, Net Cash Flow topped out at $70.0 million in Q4 2025 and bottomed at -$49.6 million in Q1 2026.
- A 5-year average of -$1.7 million and a median of -$4.4 million in 2024 frame the typical range for Net Cash Flow.
- Annual changes were most pronounced in 2024 — Net Cash Flow sank 5180.68% — and 2025, when it soared 1454.73%.
- Minerva Neurosciences' Net Cash Flow stood at -$4.1 million in 2022, then sank by 45.2% to -$6.0 million in 2023, then rose by 13.76% to -$5.2 million in 2024, then surged by 1454.73% to $70.0 million in 2025, then plunged by 170.88% to -$49.6 million in 2026.
- Business Quant data shows NERV's Net Cash Flow at -$49.6 million in Q1 2026, $70.0 million in Q4 2025, and -$2.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | 10.56 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 224.46 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -1.34 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 457.40 Mn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -152.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | 57.19 Mn |
| 10 | Minerva Neurosciences | 195.10 Mn | 195.10 Mn | - | -49.61 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -49.61 Mn |
| Mar 31, 2026 | -49.61 Mn |
| Dec 31, 2025 | 70.00 Mn |
| Dec 31, 2025 | 70.00 Mn |
| Sep 30, 2025 | -2.93 Mn |
| Sep 30, 2025 | -2.93 Mn |
| Jun 30, 2025 | -2.04 Mn |
| Jun 30, 2025 | -2.04 Mn |
| Mar 31, 2025 | -4.07 Mn |
| Mar 31, 2025 | -4.07 Mn |
| Dec 31, 2024 | -5.17 Mn |
| Dec 31, 2024 | -5.17 Mn |
| Sep 30, 2024 | -4.35 Mn |
| Sep 30, 2024 | -4.35 Mn |
| Jun 30, 2024 | -3.94 Mn |
| Jun 30, 2024 | -3.94 Mn |
| Mar 31, 2024 | -6.09 Mn |
| Mar 31, 2024 | -6.09 Mn |
| Dec 31, 2023 | -5.99 Mn |
| Dec 31, 2023 | -5.99 Mn |